Ginkgo Bioworks Holdings (DNABW) Current Deferred Revenue (2019 - 2026)

Ginkgo Bioworks Holdings has reported Current Deferred Revenue for 8 years, with the latest figure at $14.9 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 55.69% year-over-year to $14.9 million; the trailing twelve-month figure through Mar 2026 stood at $14.9 million (down 55.69% YoY), and the FY2025 full-year result was $94.1 million, down 25.61% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $14.9 million, down from $94.1 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $222.6 million in Q4 2022, with the low at $14.9 million in Q1 2026.
• Historically, Current Deferred Revenue has averaged $86.3 million across 5 years, with a median of $42.8 million in 2023.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue jumped 368.98% — and 2024, when it slumped 80.56%.
• Ginkgo Bioworks Holdings' Current Deferred Revenue stood at $222.6 million in 2022, then declined by 9.03% to $202.5 million in 2023, then slumped by 37.53% to $126.5 million in 2024, then decreased by 25.61% to $94.1 million in 2025, then plunged by 84.16% to $14.9 million in 2026.
• The last three Current Deferred Revenue figures came in at $14.9 million (Q1 2026), $94.1 million (Q4 2025), and $25.2 million (Q3 2025), per Business Quant data.